. 2021 Oct 22;9(11):1521. doi: 10.3390/biomedicines9111521

Table 3.

Multivariable-adjusted HRs and 95% CIs for an increment of one SD of Se or SELENOP for overall and CRC-specific mortality in sensitivity analyses and across strata of potential effect modifiers among CRC cases in the EPIC study.

			Overall Mortality		CRC-Specific Mortality ^a
Risk Factor		Deaths/Total	HR (95% CI) ^b	P_trend ^d _{or interaction} ^c	Deaths/Total	HR (95% CI) ^b	P_trend ^d _{or interaction} ^c
Selenium
All participants		514/993	0.91 (0.83–1.00)	0.04 ^d	395/969	0.90 (0.81–1.00)	0.06 ^d
Sensitivity analyses
Complete CRC stage data ^e		450/857	0.91 (0.82–1.00)	0.05 ^d	355/839	0.92 (0.82–1.03)	0.14 ^d
Imputed CRC stage data		514/993	0.92 (0.84–1.01)	0.07 ^d	395/969	0.91 (0.82–1.02)	0.09 ^d
Follow-up (years)
	≥2	257/732	0.94 (0.83–1.07)	0.37 ^d	165/711	0.94 (0.80–1.10)	0.42 ^d
	≥4	158/631	1.02(0.87–1.19)	0.83 ^d	77/611	1.03 (0.84–1.28)	0.76 ^d
Time between blood collection and diagnosis (years)
	<2.6	176/330	0.93 (0.78–1.12)	0.03	138/325	0.89 (0.73–1.10)	0.01
	[2.6–4.8)	175/332	0.86 (0.73–1.01)		133/321	0.84 (0.70–1.02)
	≥4.8	163/331	1.00 (0.83–1.21)		124/323	1.00 (0.80–1.25)
Stratified Analyses
Sex
	Women	252/516	0.92 (0.80–1.06)	0.52	202/505	0.93 (0.79–1.08)	0.48
	Men	262/477	0.87 (0.77–1.00)		193/464	0.86 (0.73–1.01)
Age at diagnosis (years)
	<62.4	215/497	0.94 (0.80–1.11)	0.51	184/493	0.95 (0.80–1.13)	0.38
	≥62.4	299/496	0.89 (0.79–1.00)		211/476	0.86 (0.75–0.99)
Cancer site
	Colon	333/626	0.89(0.80–1.00)	0.56	255/611	0.89 (0.78–1.01)	0.87
	Rectum	181/367	0.92 (0.77–1.09)		140/358	0.90 (0.74–1.09)
Stage ^e
	I–II	128/413	1.03 (0.84–1.25)	0.11	79/399	1.08 (0.85–1.37)	0.10
	III–IV	322/444	0.90 (0.80–1.01)		276/440	0.89 (0.78–1.01)
Region ^f
	Northern	194/330	0.79 (0.68–0.91)	0.03	158/325	0.75 (0.64–0.89)	0.01
	Central	227/436	0.97 (0.83–1.13)		163/418	0.94 (0.79–1.13)
	Southern	93/227	1.03 (0.81–1.30)		74/226	1.21 (0.92–1.58)
Selenoprotein P
All participants		513/990	0.94 (0.85, 1.03)	0.17 ^d	395/966	0.95 (0.86–1.06)	0.39 ^d
Sensitivity analyses
Complete CRC stage data ^e		450/856	0.94 (0.84, 1.04)	0.22 ^d	355/838	0.95 (0.86–1.06)	0.39 ^d
Imputed CRC stage data		513/990	0.94 (0.86, 1.04)	0.24 ^d	395/966	0.97 (0.87–1.08)	0.58 ^d
Follow-up (years)
	≥2	257/730	0.93 (0.82, 1.07)	0.31 ^d	165/709	0.97 (0.82–1.15)	0.74 ^d
	≥4	158/629	0.99 (0.83, 1.17)	0.88 ^d	77/609	1.10 (0.86–1.40)	0.45 ^d
Time between blood collection and diagnosis (years)
	<2.6	176/329	0.88 (0.74–1.05)	0.15	138/324	0.88 (0.72–1.07)	0.45
	[2.6–4.8)	175/331	0.87(0.74–1.04)		133/320	0.90 (0.74–1.10)
	≥4.8	162/330	1.06(0.88–1.28)		124/322	1.16 (0.93–1.44)
Stratified Analyses
Sex
	Women	252/514	0.91(0.79–1.06)	0.74	202/503	0.97 (0.82–1.15)	0.76
	Men	261/476	0.92(0.81–1.05)		193/463	0.92 (0.79–1.08)
Age at diagnosis (years)
	<62.4	216/497	0.91(0.78–1.07)	0.66	185/493	0.91 (0.76–1.08)	0.83
	≥62.4	297/493	0.93(0.82–1.05)		210/473	0.97 (0.84–1.12)
Cancer site
	Colon	332/626	0.94(0.84–1.06)	0.80	255/611	0.97 (0.85–1.10)	0.84
	Rectum	181/364	0.86(0.71–1.04)		140/355	0.94 (0.76–1.17)
Stage ^e
	I–II	127/410	0.95(0.78–1.15)	0.90	78/396	1.09 (0.85–1.38)	0.37
	III–IV	323/446	0.95(0.84–1.08)		277/442	0.96 (0.84–1.11)
Region ^f
	Northern	194/330	0.88(0.77–1.01)	0.49	158/325	0.90 (0.77–1.05)	0.31
	Central	226/432	0.96(0.82–1.13)		163/414	0.94 (0.78–1.14)
	Southern	93/228	1.03(0.79–1.34)		74/227	1.20 (0.88–1.62)

^a Excluded 24 cases with missing cause of death. ^b Adjusted for age, sex, stage, smoking status, BMI, site of primary tumor, year of diagnosis, and baseline diabetes. Stratified by country. ^c P for trend or interaction (as estimated by the likelihood ratio test). ^d P for trend. ^e Participants with missing data were not included in the analysis. ^f Geographic regions: Northern = Denmark; Central = UK, The Netherlands, Germany, North of France; Southern = South of France, Italy, Spain.